Seeking Alpha

More on Optimer Pharmaceuticals (OPTR): Q4 beats revenue expectations as the early launch of its...

More on Optimer Pharmaceuticals (OPTR): Q4 beats revenue expectations as the early launch of its new drug Dificid adds $11M in sales to its top line. Shares +0.9% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)